IDXX

SEC source: 0001140361-18-005648 · doc1.xml · nonDerivative · entry 4

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,438

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $182.04 to a high of $182.57 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-005648 · doc1.xml · nonDerivative · entry 3

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,638

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $181.03 to a high of $182.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-005648 · doc1.xml · nonDerivative · entry 2

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,344

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $180.01 to a high of $181.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-005648 · doc1.xml · nonDerivative · entry 1

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,040

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-005647 · doc1.xml · derivative · entry 14

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 18,000 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · price: Not applicable.

F11 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,059,112

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,059,212

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $182.02 to a high of $182.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,067,880

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $181.01 to a high of $182.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,075,412

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $180.0001 to a high of $180.7601 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-005647 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,077,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-004511 · doc1.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,628

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($5,970.88) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001140361-18-004512 · doc1.xml · nonDerivative · entry 1

Kingsley Lawrence D · CIK 0001301427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,558

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,659.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001140361-18-004510 · doc1.xml · nonDerivative · entry 1

ESSIG STUART · CIK 0001187574 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214

F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($18,659.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.

SEC source: 0001140361-18-001788 · doc1.xml · derivative · entry 14

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,000

Underlying: Common Stock · 18,000 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F9 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 10

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,059,112

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · price: Represents the weighted average sales price of the shares sold ranging from a low of $167.6001 to a high of $168.25 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 9

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,074,952

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F7 · price: Represents the weighted average sales price of the shares sold ranging from a low of $166.60 to a high of $167.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 8

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,077,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-001788 · doc1.xml · derivative · entry 13

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,000

Underlying: Common Stock · 18,000 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F9 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 7

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,059,112

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · price: Represents the weighted average sales price of the shares sold ranging from a low of $165.53 to a high of $165.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 6

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,059,416

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: Represents the weighted average sales price of the shares sold ranging from a low of $164.51 to a high of $165.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,074,912

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $163.50 to a high of $164.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,077,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-001788 · doc1.xml · derivative · entry 12

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,000

Underlying: Common Stock · 18,000 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · price: Not applicable.

F9 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,059,112

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $165.355 to a high of $165.93 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,062,812

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $164.35 to a high of $165.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-18-001788 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,077,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-18-001112 · doc1.xml · derivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,000

Underlying: Common Stock · 12,500 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-18-001112 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,059,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 39 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 29, 2017.

SEC source: 0001140361-18-000540 · doc1.xml · derivative · entry 3

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,695

Underlying: Common Stock · 2,820 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: These restricted stock units are part of a grant made to the reporting person on January 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

F4 · price: Not applicable.

F3 · derivative.exercise_date: These restricted stock units are part of a grant made to the reporting person on January 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

F3 · derivative.expiration_date: These restricted stock units are part of a grant made to the reporting person on January 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

SEC source: 0001140361-18-000540 · doc1.xml · nonDerivative · entry 2

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,438

F2 · price: Closing price of Issuer's common stock on the NASDAQ market on December 29, 2017.

SEC source: 0001140361-18-000540 · doc1.xml · nonDerivative · entry 1

MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,533

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes a total of 165 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2017, June 30, 2017, September 29, 2017 and December 29, 2017.

SEC source: 0001140361-17-045366 · doc1.xml · derivative · entry 3

MAZELSKY JAY · CIK 0001556270 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,968

Underlying: Common Stock · 961 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

F3 · price: Not applicable.

F2 · derivative.exercise_date: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

F2 · derivative.expiration_date: These restricted stock units were granted to the reporting person on December 5, 2013. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.

SEC source: 0001140361-17-045366 · doc1.xml · nonDerivative · entry 2

MAZELSKY JAY · CIK 0001556270 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,884

SEC source: 0001140361-17-045366 · doc1.xml · nonDerivative · entry 1

MAZELSKY JAY · CIK 0001556270 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,355

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 39 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 29, 2017.

SEC source: 0001140361-17-044911 · doc1.xml · nonDerivative · entry 2

TWIGGE GIOVANI · CIK 0001500399 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,402

SEC source: 0001140361-17-044911 · doc1.xml · nonDerivative · entry 1

TWIGGE GIOVANI · CIK 0001500399 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,960

F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $156.05 to a high of $156.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F2 · balance_after: Includes a total of 70 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2017 and September 29, 2017.

SEC source: 0001140361-17-043146 · doc1.xml · derivative · entry 15

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,500

Underlying: Common Stock · 18,000 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · price: Not applicable.

F10 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 11

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,046,573

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F9 · price: Represents the weighted average sales price of the shares sold ranging from a low of $153.76 to a high of $154.13 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 10

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,058,273

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · price: Represents the weighted average sales price of the shares sold ranging from a low of $152.73 to a high of $153.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 9

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,062,373

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F7 · price: Represents the weighted average sales price of the shares sold ranging from a low of $151.53 to a high of $152.51per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 8

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,064,573

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-17-043146 · doc1.xml · derivative · entry 14

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,500

Underlying: Common Stock · 18,000 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · price: Not applicable.

F10 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 7

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,046,573

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · price: Represents the weighted average sales price of the shares sold ranging from a low of $149.74 to a high of $150.08 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 6

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,056,673

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: Represents the weighted average sales price of the shares sold ranging from a low of $148.65 to a high of $149.54 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 5

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,064,573

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-17-043146 · doc1.xml · derivative · entry 13

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,500

Underlying: Common Stock · 18,000 shares

Expires 2018-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · price: Not applicable.

F10 · derivative.exercise_date: Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 4

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,046,573

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $148.93 to a high of $149.17 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 3

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,051,373

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $147.92 to a high of $148.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 2

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,059,630

F1 · shares: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $146.91 to a high of $147.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001140361-17-043146 · doc1.xml · nonDerivative · entry 1

AYERS JONATHAN W · CIK 0001184149 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,064,573

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.